Royal Marsden NHS Foundation Trust: Adenocarcinoma trials

The registry lists 13 Adenocarcinoma studies with Royal Marsden NHS Foundation Trust as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 6No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Dose Escalated Radiotherapy for Rectal Cancers Using MR-guided RadiotherapyRecruitingNCT06854679Not applicable
• Dose De-escalation in Prostate Radiotherapy Using the MRLRecruitingNCT05709496Not applicable
• Molecular Analysis of Gastric and OEsophageal Cancers STudyWithdrawnNCT06702384
• A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic BiomarkersStatus unknownNCT03840460
• Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric CancerActive, not recruitingNCT03399071Phase 2
• Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaWithdrawnNCT03361319Phase 1/2
• Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2
• Low Rectal Cancer Study (MERCURY II)Status unknownNCT02005965
• Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) TrialStatus unknownNCT01995942
• Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological CancerCompletedNCT01216813
• Avoiding Surgery in Rectal Cancer After Pre-Operative TherapyStatus unknownNCT01047969Phase 2
• Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 WeeksStatus unknownNCT01037049Phase 2
• Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal AdenocarcinomaCompletedNCT00220103Phase 2